[1]. Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.
International journal of hematology ELSEVIER （2026年） [査読] 有
[DOI] [2]. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs
Blood Advances ELSEVIER （2026年） [査読] 有
[3]. Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients.
British journal of haematology Wiley （2026年） [査読] 有
[4]. Predicting intraoperative transfusion volumes of blood products in cardiovascular surgery: a retrospective study.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis ELSEVIER [巻]65 [号]2 [頁]104374 （2026年） [査読] 有
[5]. Serum presepsin level reflects macrophage activation and hemophagocytosis in bone marrow.
PloS one [巻]21 [号]4 [頁]e0344867 （2026年） [査読] 有
[6]. Long-term immunity to measles and rubella after vaccination in adult allogeneic hematopoietic stem cell transplant recipients
INTERNATIONAL JOURNAL OF HEMATOLOGY ELSEVIER [巻]123 [号]1 [頁]92 -103 （2025年） [査読] 有
[DOI] [7]. Early Prediction of MR4.5 Attainment and Sustained Response in Chronic Myeloid Leukemia Treated with Second-Generation Tyrosine Kinase Inhibitors: Analysis from the JALSG CML212 Road to MR4.5 Study.
HemaSphere Wiley [巻]9 （2025年） [査読] 有
[8]. The EUTOS Long-Term Survival Score Predicts Failure-Free Survival in Chronic Myeloid Leukemia Patients in the Era of Second-Generation Tyrosine Kinase Inhibitors: Analysis from the JALSG-JSH CML Study.
HemaSphere Wiley [巻]9 （2025年） [査読] 有
[9]. Bosutinib for Successful Treatment- Free Remission in Chronic Myeloid Leukemia.
Cancer Medicine WILEY [巻]14 [号]9 [頁]e70822 （2025年） [査読] 有
[DOI] [10]. Nilotinib vs dasatinib in achieving MR 4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study
BLOOD ADVANCES [巻]8 [号]20 [頁]5237 -5247 （2024年） [査読] 有
[DOI] [11]. The development and evanescence of red blood cell antibodies after transfusion: A multi-institutional prospective study in Japan.
Transfusion （2024年） [査読] 有
[12]. Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic Anemia
Journal of Hematology （2024年） [査読] 有
[13]. A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment.
Clinics and practice [巻]14 [号]4 [頁]1216 -1224 （2024年） [査読] 有
[14]. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML
CANCER SCIENCE WILEY [巻]114 [号]3 [頁]995 -1006 （2023年） [査読] 有
[DOI] [15]. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Blood [巻]141 [号]10 [頁]1159 -1168 （2023年） [査読] 有
[DOI] [16]. Identification of skin-infiltrating donor lymphocytes in a case of pre-engraftment syndrome
JOURNAL OF DERMATOLOGY （2023年） [査読] 有
[DOI] [17]. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01
CANCER SCIENCE （2023年） [査読] 有
[DOI] [18]. Characterization of endogenous markers of hepatic function in patients receiving itraconazole treatment for prophylaxis of deep mycosis
JOURNAL OF INFECTION AND CHEMOTHERAPY [巻]29 [号]3 [頁]244 -249 （2023年） [査読] 有
[DOI] [19]. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
INTERNATIONAL JOURNAL OF HEMATOLOGY Springer [巻]116 [号]6 [頁]871 -882 （2022年） [査読] 有
[DOI] [20]. Effect of Early Nutritional Support on Quality of Life by EORTC QLQ-C30 in Allogeneic Hematopoietic Stem Cell Transplantation.
Blood cell therapy [巻]5 [号]4 [頁]107 -115 （2022年） [査読] 有
[DOI] [21]. HM-SCREEN-Japan 01: a mutation profiling multicenter study on patients with acute myeloid leukemia
ANNALS OF ONCOLOGY [巻]33 [頁]S469 -S469 （2022年） [査読] 有
[DOI] [22]. Emerging molecular targets in AML: IDH1/2-and menin-related mutations (HM-SCREEN-JAPAN01)
ANNALS OF ONCOLOGY [巻]33 [頁]S487 -S487 （2022年） [査読] 有
[DOI] [23]. Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia
JOURNAL OF PHARMACOLOGICAL SCIENCES [巻]149 [号]3 [頁]158 -165 （2022年） [査読] 有
[DOI] [24]. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
INTERNATIONAL JOURNAL OF HEMATOLOGY [巻]115 [号]6 [頁]838 -851 （2022年） [査読] 有
[DOI] [25]. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
International journal of hematology [巻]115 [号]6 [頁]838 -851 （2022年） [査読] 有
[26]. Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.
Leukemia research reports [巻]17 [頁]100312 （2022年） [査読] 有
[DOI] [27]. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow up of the Japanese subgroup of the randomized ENESTnd trial.
Int J Hematol [巻]115 [号]1 [頁]33 -42 （2022年） [査読] 有
[28]. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.
Lancet Haematol. [巻]8 [号]12 [頁]e902 -e911 （2021年） [査読] 有
[29]. Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
Cancers Cancers(Basel) [巻]13 [号]20 [頁]5116 （2021年） [査読] 有
[30]. A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.
J Clin Exp Hematop [巻]61 [号]3 [頁]162 -167 （2021年） [査読] 有
[31]. Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation.
Int J Hematol [巻]114 [号]2 [頁]252 -262 （2021年） [査読] 有
[32]. Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial.
International journal of cancer [巻]148 [号]6 [頁]1462 -1469 （2021年） [査読] 有
[DOI] [機関リポジトリ][33]. Associations between plasma hydroxylated metabolite of itraconazole and serum creatinine in patients with a hematopoietic or immune-related disorder.
European journal of clinical pharmacology [巻]77 [号]3 [頁]369 -379 （2021年） [査読] 有
[DOI] [34]. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
Cancer science [巻]111 [号]10 [頁]3714 -3725 （2020年） [査読] 有
[DOI] [35]. Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.
International journal of hematology [巻]112 [号]3 [頁]409 -417 （2020年） [査読] 有
[DOI] [36]. Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including -desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application.
Journal of pharmaceutical health care and sciences [巻]6 [頁]11 （2020年） [査読] 有
[DOI] [37]. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
International Journal of Hematology Springer [巻]112 [号]1 [頁]24 -32 （2020年） [査読] 有
[DOI] [38]. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Internal medicine (Tokyo, Japan) [巻]58 [号]11 [頁]1577 -1581 （2019年） [査読] 有
[DOI] [39]. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
International journal of hematology [巻]109 [号]4 [頁]426 -439 （2019年） [査読] 有
[DOI] [40]. [Sarcoidosis-lymphoma syndrome showing abnormal FDG uptake in lymph nodes and muscles upon post-chemotherapy PET/CT imaging].
[Rinsho ketsueki] The Japanese journal of clinical hematology [巻]60 [号]4 [頁]302 -307 （2019年） [査読] 有
[DOI] [41]. Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag.
Case reports in cardiology [巻]2019 [頁]2756319 （2019年） [査読] 有
[DOI] [42]. Correction to: Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
International journal of hematology [巻]108 [号]5 [頁]564 （2018年） [査読] 有
[DOI] [43]. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
International journal of hematology [巻]108 [号]5 [頁]524 -534 （2018年） [査読] 有
[DOI] [44]. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
International journal of hematology [巻]107 [号]3 [頁]327 -336 （2018年） [査読] 有
[DOI] [45]. Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.
International journal of hematology [巻]105 [号]5 [頁]638 -645 （2017年） [査読] 有
[DOI] [46]. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.
Blood cancer journal [巻]5 [頁]e285 （2015年） [査読] 有
[DOI] [47]. Epstein-Barr virus-associated T-cell lymphoproliferative disorder affecting skin and lung in an elderly patient.
The Journal of dermatology [巻]41 [号]9 [頁]837 -40 （2014年）
[DOI] [48]. Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
[Rinsho ketsueki] The Japanese journal of clinical hematology [巻]55 [号]5 [頁]558 -62 （2014年）
[49]. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Cancer science [巻]105 [号]1 [頁]97 -104 （2014年） [査読] 有
[DOI] [50]. Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.
Cancer science [巻]103 [号]11 [頁]1974 -8 （2012年） [査読] 有
[DOI] [51]. [Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan [巻]132 [号]5 [頁]675 -81 （2012年）
[DOI] [52]. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
Leukemia research [巻]35 [号]5 [頁]598 -603 （2011年） [査読] 有
[DOI] [53]. Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study.
Haematologica [巻]96 [号]1 [頁]174 -6 （2011年） [査読] 有
[DOI] [54]. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
Carcinogenesis [巻]31 [号]11 [頁]2012 -21 （2010年）
[DOI] [55]. Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.
Investigational new drugs [巻]28 [号]4 [頁]381 -91 （2010年）
[DOI] [56]. Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
The Journal of biological chemistry [巻]285 [号]9 [頁]6585 -94 （2010年）
[DOI] [57]. Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
The Journal of biological chemistry [巻]284 [号]33 [頁]22155 -65 （2009年）
[DOI] [58]. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
British journal of haematology [巻]146 [号]1 [頁]34 -43 （2009年）
[DOI] [59]. KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells.
Leukemia research [巻]32 [号]9 [頁]1358 -65 （2008年）
[DOI] [60]. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Leukemia research [巻]32 [号]6 [頁]962 -71 （2008年）
[DOI] [61]. Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma.
European journal of haematology [巻]77 [号]1 [頁]14 -8 （2006年）
[DOI] [62]. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells.
Experimental hematology [巻]34 [号]6 [頁]736 -44 （2006年）
[DOI] [63]. Severe neutropenia with gelatinous bone marrow transformation in anorexia nervosa: a case report.
The International journal of eating disorders [巻]33 [号]3 [頁]360 -3 （2003年）
[DOI] [64]. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
British journal of haematology [巻]117 [号]4 [頁]882 -5 （2002年）
[DOI]